If you have bullous pemphigoid on your feet, try not to stand or walk for too long. Some people have bullous pemphigoid in their mouth, and that can make eating and drinking challenging.

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s decision ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.

Find the latest Wound Management news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

Approval of the injectable interleukin (IL)-4 receptor alpha antagonist was supported by data on 106 adults with moderate-to-severe bullous pemphigoid from the phase II/III ADEPT trial, which ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and ...

The phase 2/3 LIBERTY-BP ADEPT trial (ClinicalTrials.gov Identifier: NCT04206553) evaluated the safety and efficacy of dupilumab, an interleukin-4 receptor antagonist, in 106 adults with moderate ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in ...